PARTNER WITH US DOWNLOAD FULL EVENT GUIDE REGISTER HERE Welcome to the BCMA Targeted Therapies Summit Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite…Read more
Myeloma Paper of the Day, April 22nd, suggested by Robert Orlowski / BRAF mutations, cancer, KRAS mutation, MD Anderson Cancer Cente, monoclonal plasma cell
Myeloma Paper of the Day, April 21st, suggested by Robert Orlowski / BCMA CAR-T cell therapy, cancer, CD19 CAR-T cells, MD Anderson Cancer Center, multiple
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
A physician who has worked with unmatched applicants explains how to make the most of the coming year and improve the odds of matching in…
This study on anti-MAG neuropathy provides updated insights into the epidemiology of this disease, clinical profiles, and treatment approaches in Japan. Rituximab therapy, used for…
Gain/amplification of 1q21 (≥3 copies), a chromosomal abnormality frequently observed in multiple myeloma, can negatively affect prognosis, due to its involvement in resistance to anti-myeloma…
Program: Oral and Poster Abstracts Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational…
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) for…
